Reviews/Targeted Therapy Breast Cancer/Sacituzumab in third-line triple-negative breast cancer
Brca Dna · BC-TNBC-02 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
One large randomized trial, ASCENT, tested sacituzumab govitecan against single-agent chemotherapy in people with metastatic triple-negative breast cancer who had already been treated, and found patients lived longer on the drug (12.1 vs 6.7 months) [11]. The same trial confirmed this at its final analysis [4] and in a randomized subgroup [8]. A single-arm study [12] and a real-world dataset [6] report similar survival times but had no comparison group, so they cannot show the drug is better than chemotherapy on their own. A critical appraisal [18] argues that several features of ASCENT's design may have made the comparison look more favourable to the drug. The panel judged the survival benefit large and on a hard endpoint, while noting it rests on just one open-label trial.
The corpus contains one pivotal randomized phase 3 trial, ASCENT, reporting a statistically significant overall survival benefit for sacituzumab govitecan over physician's-choice chemotherapy in pre-treated mTNBC (12.1 vs 6.7 months, HR 0.48) [11], upheld at final analysis (11.8 vs 6.9 months, HR 0.51) [4] and in a randomized subgroup (12.4 vs 6.7 months, HR 0.44) [8]. Uncontrolled data concur on survival magnitude: a single-arm phase II reported median OS 16.6 months [12] and a real-world series 12.43 months [6], but neither has a comparator. A critical appraisal documents four design features of ASCENT said to favour the experimental arm [18]. No second randomized comparative trial in this exact population and endpoint appears in the corpus. The contested point: The division is over the magnitude and robustness of the comparative OS benefit rather than its direction: the comparative signal comes from a single open-label trial whose control arm [18] calls restricted and 'substandard', and whose OS was a secondary rather than primary endpoint. There is no independent randomized replication in the corpus to arbitrate whether the observed advantage reflects true standard-of-care comparison.
All 19 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Targeted Therapy Breast Cancer, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The comparative OS benefit rests on a single randomized trial (ASCENT); [8] is a subset of it and [6]/[12] are uncontrolled, so there is no independent randomized replication in the corpus.
OS was a secondary endpoint in ASCENT (PFS was primary), so the OS finding carries less protection against multiplicity and chance than a pre-specified primary endpoint.
Where it remains uncertain. The entire comparative signal rests on one open-label trial; OS was a secondary endpoint and a critical appraisal argues the control arm was restricted and 'substandard' [18], while the supportive data [12][6] have no comparator.
Aleatory
OS was a secondary endpoint behind PFS in ASCENT [11][4], so the finding carries less protection against multiplicity and chance than a pre-specified primary endpoint.
Epistemic
The comparative signal comes from one trial; [8] is a subset of ASCENT and [6][12] are uncontrolled, so no second randomized comparative trial in the corpus can confirm the magnitude.
Inferential
[18] argues four design features favouring the experimental arm leave it 'uncertain in which extent the reported outcomes will translate in the real world'; the real-world series [6] is uncontrolled and cannot settle this.
The load-bearing papers from a corpus of 19, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Final ASCENT analysis confirms durable OS benefit over chemotherapy
“SG (n = 267) improved median progression-free survival (PFS; 4.8 v 1.7 months; hazard ratio (HR), 0.41 [95% CI, 0.33 to 0.52]) and median overall survival (OS; 11.8 v 6.9 months; HR, 0.51 [95% CI, 0.42 to 0.63]) over TPC (n = 262).”
Panel auditInternal validity: high · scope of inference: Metastatic TNBC in the second line or later (pre-treated).Key limitations: open-label · OS is a secondary endpoint
Randomized subgroup confirms OS benefit, though within the same trial
“median overall survival was 12.4 versus 6.7 months (HR 0.44; 95% CI 0.30-0.64)”
Panel auditInternal validity: medium · scope of inference: Pre-treated mTNBC patients who did not have TNBC at their initial diagnosis.Key limitations: subgroup analysis · open-label parent trial
Primary RCT evidence of significant OS benefit in pre-treated mTNBC vs physician's-choice chemo
Panel auditInternal validity: high · scope of inference: Relapsed or refractory metastatic TNBC with prior taxane use (pre-treated), patients without brain metastases.Key limitations: open-label · primary analysis excluded brain-metastasis patients
Real-world OS consistent with trial data; uncontrolled
“the median overall survival (OS) was 12.43 months (95% CI, 7.97 months-not reached)”
Panel auditInternal validity: low · scope of inference: Real-world SG use in pre-treated metastatic TNBC under routine clinical practice.Key limitations: no comparator · retrospective · small sample
4 of 19 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A large, replicated, statistically significant OS benefit on a hard endpoint from the pivotal RCT directly supports the claim, tempered only by single-trial reliance and acknowledged design-bias concerns.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No independent randomized replication. The entire comparative OS claim rests on a single trial, ASCENT [11][4][8]; without a second comparative RCT the magnitude cannot be externally confirmed. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: An independent randomized controlled trial of sacituzumab govitecan versus standard chemotherapy in pre-treated mTNBC with OS as a pre-specified endpoint.
Open question: Does the ASCENT overall survival benefit replicate in an independent randomized trial against standard chemotherapy? Why it is still open: The corpus has only one comparative trial [11][4] plus its subset [8] and uncontrolled data [6][12], with no second randomized comparison.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 23 Oct 2026 · protocol v0.19